Korro Bio, Inc. - Common Stock (KRRO)
8.2300
+0.3300 (4.18%)
NASDAQ · Last Trade: Dec 12th, 6:36 PM EST

Industry veterans John Maraganore, Ph.D., and Rachel Meyers, Ph.D., to provide strategic guidance on the company’s RNA Actuating platform to develop a new class of RNA medicines that upregulate protein coding genes
By CAMP4 Therapeutics · Via GlobeNewswire · December 10, 2024

The European Central Bank cut interest rates for the second time in about three months prior the FOMC's interest rate announcement, European stocks may benefit.
Via MarketBeat · September 22, 2024
